Anti-HER2 monoclonal antibodies such as trastuzumab and targeted small molecules may be used to treat HER-2 positive breast cancer, however many challenges remain to achieve optimal clinical outcomes for the HER2 subtype [1,2,3]. This evidence concerns the gene ERBB2 and breast cancer.